MELANOMA STAGE IV

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation to melanoma cells. It is for people with advanced melanoma that has not responded to prior therapies. The trial will evaluate safety and effectiveness when given alone or with the immunotherap…

This study tests whether two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 adults with stage III or IV melanoma will receive the combination. The goal is to control the disease by blockin…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 participants will receive treatment based on their tumor's biomarkers. The goal is to see if this approach leads to a major or complete response …

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to attack cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The mai…

This study looks at whether giving extra treatment after surgery can lower the chance of melanoma coming back in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 adults will receive a combination of two drugs (encorafenib and binimetinib) befo…

This early-stage study tests an experimental oral drug called GIM-531 in people with advanced solid tumors (including stage IV melanoma) that have stopped responding to standard treatments. The drug works by targeting certain immune cells to help the body fight cancer. Researcher…

This study looks at whether adding precise radiation to the brain (stereotactic radiotherapy) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) helps people with melanoma that has spread to the brain live longer without neurological complications. About 218 a…

This study is for people with high-risk melanoma who have had surgery to remove their cancer. It uses a special blood test to look for tiny bits of tumor DNA left in the body. If found, participants receive either a combination of two immunotherapy drugs or one drug alone to try …

This early-stage trial tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that have a marker called NY-ESO-1. The study includes people with advanced cancers like sarcoma, melanoma, breast, lung, bladder, and ova…

This study is for people with advanced melanoma (stage III or IV that cannot be removed by surgery) whose cancer has stopped responding to standard immunotherapy drugs like nivolumab or pembrolizumab. The trial tests a new sequence of three drugs: high-dose interleukin-2 (IL2) pl…

This study looks at how beta-glucan, a natural fiber found in foods like oats and mushrooms, affects the immune system in people with stage III or IV melanoma who are already taking the immunotherapy drug pembrolizumab. Researchers will measure changes in immune cells from blood …

This study looks at whether combining a special PET/CT scan with a blood test for tumor DNA can help doctors predict which patients with advanced melanoma will respond to immunotherapy. Researchers will compare changes in the scan and blood test results from before treatment to a…

This study follows about 40 people who received a Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer over the long term. The goal is to better understand the lasting safety and effects of this treatment…